Lineage Cell Therapeutics, Inc. (LCTX)
1.025
+0.08
(+8.17%)
USD |
NYAM |
Oct 08, 16:00
1.025
0.00 (0.00%)
After-Hours: 18:53
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 259.23M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | -45.23% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | 19.48 |
| Price to Book Value | 4.256 |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | 0.0377 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 87.55% |
Profile
| Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. The company's pipeline consists of seven allogeneic cell transplant therapy programs spanning clinical to research stages, targeting a range of conditions including dry-AMD, spinal cord injuries, auditory neuropathy, Type 1 Diabetes, and vision loss, with several programs supported by strategic partnerships with Roche, Genentech, William Demant Invest, and Factor Biosciences. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA. |
| URL | http://www.lineagecell.com |
| Investor Relations URL | https://investor.lineagecell.com |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap Growth |
| Next Earnings Release | Nov. 05, 2026 (est.) |
| Last Earnings Release | Aug. 06, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. The company's pipeline consists of seven allogeneic cell transplant therapy programs spanning clinical to research stages, targeting a range of conditions including dry-AMD, spinal cord injuries, auditory neuropathy, Type 1 Diabetes, and vision loss, with several programs supported by strategic partnerships with Roche, Genentech, William Demant Invest, and Factor Biosciences. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA. |
| URL | http://www.lineagecell.com |
| Investor Relations URL | https://investor.lineagecell.com |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap Growth |
| Next Earnings Release | Nov. 05, 2026 (est.) |
| Last Earnings Release | Aug. 06, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |